Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
ELCCG-CSF Use in Small Cell Lung Cancer: New Data 'Comforting' Although patients with SCLC given granulocyte colony-stimulating factors during chemo-radiotherapy had an increased risk for hematologic complications, the drugs can be used safely, say researchers.
Medscape Medical News, May 9, 2017
ELCCQuestions Over 'Flu Jab' in Lung Cancer Patients on PD Inhibitors Patients with cancer receiving immune checkpoint inhibitors could be at increased risk for adverse events compared with the general population if they are given a yearly flu jab, say Swiss researchers.
Medscape Medical News, May 8, 2017
ELCCPD-Inhibitor Benefits 'Continue Beyond Progression' in NSCLCNon-small cell lung cancer patients can benefit from immunotherapy even after progression, from both drug continuance and the ongoing effect of prior treatment on salvage therapy, reveal two studies.
Immunotherapies for NSCLC 'Perform Well in Real World'The anti-PD-1 agents nivolumab and pembrolizumab achieve real-world outcomes comparable to that seen in trials, although survival
is closely linked to patient performance status.
Doubts Over PD Inhibitor Plus TKI Combo in NSCLCCombining checkpoint inhibitors with tyrosine kinase inhibitors in non-small cell lung cancer adds little benefit but substantially
increases serious adverse events.